## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: PEG 1.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($696.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. How Is The Market Feeling About Regeneron Pharmaceuticals Inc?**
- Source: Sahm | 20251211T070917 | Somewhat-Bearish | Relevance: 100%
- Regeneron Pharmaceuticals Inc.'s short interest has increased by 10.49% since its last report, with 3.15 million shares sold short, representing 3.16% of available shares. This higher short interest suggests a more bearish market sentiment towards the stock, although its 3.16% short interest is still lower than the peer group average of 6.93%. Traders should be aware of this increase in shorted shares.

**2. How Investors May Respond To Regeneron (REGN) Lynozyfic Multiple Myeloma Data And Frontline Oncology Ambitions**
- Source: Simply Wall Street | 20251211T044726 | Somewhat-Bullish | Relevance: 100%
- Regeneron Pharmaceuticals' Lynozyfic (linvoseltamab) monotherapy shows strong early data in newly diagnosed multiple myeloma patients, indicating its potential as a frontline treatment. While these results bolster Regeneron's oncology ambitions and pipeline, the company's investment narrative still largely depends on offsetting EYLEA competition with new blockbusters and diversified revenue streams. Investors must weigh the promising oncology developments against ongoing challenges in its established markets.

**3. Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial**
- Source: WHTC | 20251210T172024 | Bullish | Relevance: 100%
- A small mid-stage trial suggests that Regeneron's recently approved antibody drug, Lynozyfic, can eliminate residual multiple myeloma cells after initial treatments, potentially negating the need for bone marrow transplants. The article also touches on a study indicating GLP-1 drugs do not reduce cancer risks and another linking pre-teen smartphone ownership to higher risks of depression, obesity, and insufficient sleep.

**4. Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery**
- Source: BioSpace | 20251210T050857 | Bullish | Relevance: 100%
- After a challenging year marked by regulatory rejections and manufacturing issues that saw its shares drop to a four-year low of $483, Regeneron has rebounded significantly. The company's stock has climbed back to $787, exceeding its January 1st price of $715 and showing a 10% increase for the year, driven by renewed analyst optimism and recent critical approvals for its Eylea drug. Looking ahead, Regeneron is poised for further growth, particularly with the continued success of Dupixent and potential reduced regulatory burdens for its pipeline assets under new FDA guidelines.

**5. Regeneron (REGN): Revisiting Valuation After a Short-Term Pullback and Longer-Term Shareholder Weakness**
- Source: Simply Wall Street | 20251210T023345 | Somewhat-Bullish | Relevance: 100%
- Regeneron Pharmaceuticals (REGN) has experienced a short-term pullback despite a strong 90-day performance. The stock is considered 9.9% undervalued with a narrative fair value of approximately $768, driven by the success of EYLEA HD and anticipated regulatory approvals. Investors are evaluating whether this pullback presents a new buying opportunity or if future growth is already accounted for.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $768 | $767 | +0% |
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($1.41M) |
| Sells | 12 ($16.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $17M sold (12 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 6 raises (avg +13%) could attract flows.
- Momentum building: MRS_10 improving +10.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (6 raises, avg +13%). Insider selling cluster ($16.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $78.6B |
| Beta | 0.37 |
| 52W Range | $476.49 - $790.98 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 19.3 |
| Current P/E | 17.2 |
| YoY Growth | -11.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -6.8% to 3.2% (+10.1% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 67th percentile. MRS_5 at 4.1% confirms short-term momentum alignment. Outperforming sector by 3.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-5.93), momentum weakening. RSI neutral at 59. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.24% (CS: 67) | Strong |
| RSI_14 | 58.8 | Neutral |
| MACD Histogram | -5.93 | Bearish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 1.122x | Above |
| vs SMA200 | 1.237x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $741.29
- **Stop Loss:** $696.97 (6.0% risk)
- **Target:** $785.61 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 22
- **Position Value:** $16,308.38
- **Portfolio %:** 16.31%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*